ADPT
Income statement / Annual
Last year (2023), Adaptive Biotechnologies Corporation's total revenue was $170.28 M,
a decrease of 8.11% from the previous year.
In 2023, Adaptive Biotechnologies Corporation's net income was -$225.25 M.
See Adaptive Biotechnologies Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$170.28 M
|
$185.31 M
|
$154.34 M
|
$98.38 M
|
$85.07 M
|
$55.66 M
|
$38.45 M
|
| Cost of Revenue |
$75.55 M |
$57.91 M |
$49.30 M |
$22.53 M |
$22.27 M |
$19.67 M |
$15.68 M |
| Gross Profit |
$94.72 M |
$127.40 M |
$105.04 M |
$75.85 M |
$62.80 M |
$36.00 M |
$22.77 M |
| Gross Profit Ratio |
0.56 |
0.69 |
0.68 |
0.77 |
0.74 |
0.65 |
0.59 |
| Research and Development
Expenses |
$122.12 M
|
$141.76 M
|
$142.34 M
|
$116.07 M
|
$70.71 M
|
$39.16 M
|
$32.00 M
|
| General & Administrative
Expenses |
$83.93 M
|
$88.53 M
|
$74.50 M
|
$49.54 M
|
$30.33 M
|
$20.41 M
|
$15.95 M
|
| Selling & Marketing
Expenses |
$88.58 M
|
$95.60 M
|
$95.47 M
|
$61.36 M
|
$38.45 M
|
$24.49 M
|
$16.77 M
|
| Selling, General &
Administrative Expenses |
$172.51 M
|
$184.13 M
|
$169.97 M
|
$110.89 M
|
$68.79 M
|
$44.90 M
|
$32.71 M
|
| Other Expenses |
$27.13 M |
$1.70 M |
$1.70 M |
$1.70 M |
$1.70 M |
$1.70 M |
$1.69 M |
| Operating Expenses |
$321.76 M |
$327.59 M |
$314.01 M |
$228.67 M |
$141.19 M |
$85.75 M |
$66.40 M |
| Cost And Expenses |
$397.31 M |
$385.49 M |
$363.31 M |
$251.20 M |
$163.46 M |
$105.42 M |
$82.08 M |
| Interest Income |
$15.53 M |
$4.06 M |
$1.67 M |
$6.59 M |
$9.79 M |
$3.31 M |
$1.64 M |
| Interest Expense |
$13.80 M |
$4.24 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$22.23 M
|
$28.15 M
|
$20.98 M
|
$11.74 M
|
$7.79 M
|
$6.00 M
|
$5.80 M
|
| EBITDA |
-$189.27 M
|
-$167.98 M
|
-$193.35 M
|
-$144.35 M
|
-$70.60 M
|
-$43.76 M
|
-$37.84 M
|
| EBITDA Ratio |
-1.11 |
-1.05 |
-1.34 |
-1.54 |
-0.9 |
-0.79 |
-0.96 |
| Operating Income Ratio
|
-1.33
|
-1.08
|
-1.35
|
-1.55
|
-0.92
|
-0.89
|
-1.16
|
| Total Other
Income/Expenses Net |
$1.73 M
|
-$182,000.00
|
$1.67 M
|
$6.59 M
|
$9.79 M
|
$3.31 M
|
$1.64 M
|
| Income Before Tax |
-$225.30 M |
-$200.37 M |
-$207.30 M |
-$146.23 M |
-$68.61 M |
-$46.45 M |
-$42.83 M |
| Income Before Tax Ratio
|
-1.32
|
-1.08
|
-1.34
|
-1.49
|
-0.81
|
-0.83
|
-1.11
|
| Income Tax Expense |
$0.00 |
-$57.90 M |
-$1.69 M |
-$6.59 M |
-$9.79 M |
$3.31 M |
-$804,000.00 |
| Net Income |
-$225.25 M |
-$142.46 M |
-$205.61 M |
-$139.64 M |
-$58.82 M |
-$46.45 M |
-$42.83 M |
| Net Income Ratio |
-1.32 |
-0.77 |
-1.33 |
-1.42 |
-0.69 |
-0.83 |
-1.11 |
| EPS |
-1.56 |
-1 |
-1.46 |
-1.06 |
-0.85 |
-0.44 |
-0.41 |
| EPS Diluted |
-1.56 |
-1 |
-1.46 |
-1.06 |
-0.85 |
-0.44 |
-0.41 |
| Weighted Average Shares
Out |
$144.38 M
|
$142.52 M
|
$140.35 M
|
$131.22 M
|
$69.17 M
|
$105.43 M
|
$105.43 M
|
| Weighted Average Shares
Out Diluted |
$144.38 M
|
$142.52 M
|
$140.35 M
|
$131.22 M
|
$69.17 M
|
$105.43 M
|
$105.43 M
|
| Link |
|
|
|
|
|
|
|
